Month: January 2026

Harmattan AI’s $200 million Series B led by Dassault Aviation Paris – Saint-Cloud, France, January 12, 2026 – Dassault Aviation and Harmattan AI today announced a strategic partnership to accelerate the integration of controlled autonomy and AI technologies into combat aviation systems. As part of this collaboration, Dassault Aviation is leading Harmattan AI’s $200 million Series B funding round. Harmattan AI has been awarded multiple Programs of Record by the French and UK Ministries of Defence for its autonomous systems portfolio and is now scaling globally in response to growing demand. The proceeds from this investment round will be used to expand the deployment of AI-enabled missions across new operational theaters, extend Harmattan AI’s product offering into new domains and scale industrial manufacturing of its ISR, drone interception,...

Comment from Fund Manager Viljar Arakas Excluding revaluations of investment properties, EfTEN Real Estate Fund AS achieved the strongest operating results in its history in 2025. The Fund’s consolidated rental income increased by 3.1% compared to the previous year, driven primarily by the addition of new logistics centres and elderly care facilities to the investment portfolio. Overall vacancy across the Fund’s property portfolio remained at a low level. In addition to revenue growth, the Fund’s results were positively affected by a decrease in interest expenses resulting from the decline in EURIBOR. At the end of 2025, the weighted average interest rate on the Fund’s bank loans amounted to 3.99%, which is 0.9 percentage points lower than a year earlier. As a result of higher rental income and lower interest expenses, EfTEN Real Estate...

The total number of digital subscriptions of AS Ekspress Grupp increased by 7% in the Baltic States year-over-year (4th quarter: 5%) and totalled 255 964 at the end of December.The number of digital subscriptions of AS Delfi Meedia that publishes the news portal Delfi, newspapers Maaleht, Eesti Ekspress and several popular magazines increased by 9% year-over-year (4th quarter: 3%) and totalled 124 637. The number of digital subscriptions of AS Õhtuleht Kirjastus, 50% of which is owned by Ekspress Grupp, decreased by -4% year-over-year (4th quarter: -2%) and totalled 24 284. The number of digital subscriptions of Geenius Meedia OÜ decreased by -15% year-over-year (4th quarter: -8%) and totalled 6224. In Latvia, the number of digital subscriptions of Delfi A/S increased by 14% year-over-year (4th quarter: 22%) and totalled 40 090. In Lithuania,...

Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetesApproval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D patients Teizeild represents a potential significant change in the treatment of autoimmune T1D, preventing the natural disease progression protecting beta-cell functionParis, January 12, 2026. The European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients eight years of age and older with stage 2 T1D. This follows the positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use. Teizeild is the first T1D disease-modifying therapy approved in the EU, marking a significant milestone in the treatment of this progressive...

REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), January 12, 2026, 7:00 am CET / 1:00 am ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BNP Paribas Asset Management On January 8, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management SA. Based on the notification, BNP Paribas Asset Management Europe SAS holds 1,409,791 voting rights, representing 3.28% of the total number of voting rights on December 31, 2025 (43,026,460). The notification dated January 7, 2026 contains the following information:Reason for the notification: acquisition or disposal of voting securities or voting rights Notification...

WISeKey, together with its Subsidiaries, WISeSat and SEALSQ, to Partner with Kaynes Technology’s Satellite Subsidiary KSTPL, to Manufacture Post-Quantum Secure WISeSats Satellites in India and Establish India as a Strategic Launch HubGeneva, Switzerland / Bengaluru, India: January 12, 2026 – WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that its subsidiary, WISeSat.Space (“WISeSat”), a global leader in secure satellite and critical digital satellite infrastructure, signed a strategic cooperation agreement with Kaynes Technology India Limited (Kaynes Technology) satellite subsidiary Kaynes Space Technology Private Limited (“KSTPL”), to manufacture post-quantum-secure WISeSat satellites in India and establish India as one of its official...

Allschwil, Switzerland – January 12, 2026Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 10:30 am PST / 7:30 pm CET. The conference will take place at the Westin St. Francis hotel in San Francisco, USA. Dr Gupta will share how, with two products entering value-acceleration phase and an innovative pipeline poised to deliver the next generations of breakthrough medicines, Idorsia is on a path to profitability and growth. Follow this link to access the live audio stream. A replay will be available on the company website after the event under Investors / News & Events. Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented: “Idorsia represents a rare combination: A commercial-stage...

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 January 2026 – 7:00 AM CET Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder focused on the health and wellness segment in California. The transaction was previously announced in September 2025 and has now closed following customary clearance. UCP is based in San Diego and has strong positions in hormones and urology, alongside a solid compliance record. The business is highly complementary to Anazao and supports Fagron’s strategy to build a nationwide platform in the United States, spanning both 503A (patient...

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026 Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches Successfully advanced four new pipeline molecules in 2025; three new molecules to enter Phase 1 in 2026, contributing to total of 10 clinical-stage molecules by year-end January 12, 2026, 7:00 a.m. CET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported preliminary...